1. Home /
  2. Biotechnology

Biotechnology

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.

Short-Seller Left Goes Long on Invitae With $100 Target

Short-Seller Left Goes Long on Invitae With $100 Target

Citron analyst sees 'indestructible moat' around genetic-testing company's business.

Biggest Earnings Wednesday: GE, AMC Networks, Spotify and More

Biggest Earnings Wednesday: GE, AMC Networks, Spotify and More

Another day, another busy earnings day! What to watch on Wednesday, July 31, 2019.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

Let's check out the latest charts and indicators.

Pfizer Deal Might Be Good Treatment for Mylan

Pfizer Deal Might Be Good Treatment for Mylan

But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.